Trial Profile

An Open-label, Single-Dose, Three-way Crossover Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents (12 to 17 Years of Age) and Young Adults (18 to 24 Years of Age) With Seasonal Allergic Rhinitis

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 17 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azelastine (Primary) ; Azelastine/mometasone (Primary) ; Mometasone (Primary)
Indications Seasonal allergic rhinitis
Focus Pharmacokinetics
Sponsors Lek Pharmaceuticals d.d.; Sandoz

26 Sep 2023 Status changed from recruiting to discontinued (Business decision (no safety concerns)).
28 Aug 2023 Planned End Date changed from 26 Aug 2023 to 13 Sep 2023.
28 Aug 2023 Planned primary completion date changed from 26 Aug 2023 to 13 Sep 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com